SR33805 oxalate 

SR33805 oxalate is a potent Ca²⁺ channel antagonist, with EC₅₀s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 oxalate blocks L-type but not T-type Ca²⁺ channels. SR33805 oxalate can be used for the research of acute or chronic failing hearts^[1][2].

SR33805 (0.01-10 µM; 3 d) oxalate inhibits growth factor-induced proliferation of SMC (0.2050<0.46 µM) in a dose-dependent manner^[3].
SR33805 (10 µM; 10 min) oxalate restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca²⁺ transient amplitude^[2].
SR33805 (10 µM) oxalate decreases the activity of recombinant PKA^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats^[2].
SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

654.77

C₃₄H₄₂N₂O₉S

121346-33-6

O=S(C1=CC=C(OCCCN(C)CCC2=CC=C(OC)C(OC)=C2)C=C1)(C(N3C)=C(C(C)C)C4=C3C=CC=C4)=O.O=C(O)C(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Romey G, et, al. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22; 263(1-2): 101-5.  [Content Brief]

  [2]. Mou YA, et, al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1; 91(3): 412-9.  [Content Brief]

  [3]. Hainaud P, et, al. The calcium inhibitor SR33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis. 2001 Feb 1; 154(2): 301-8.  [Content Brief]